Lipella Pharmaceuticals, Inc. (LIPO) Stock Price & Analysis

LIPO Stock Chart & Stats

$0.03$0.00(0.00%)

At close: Aug 31 4:00 PM EDT

Day’s Range: $0.03 - $0.03
52-Week Range: $0.02 - $0.64
Previous Close: $0.03
Volume: 3
Average Volume (3M): 23.30K
Market Cap: $2,773
Enterprise Value: -$1.34T
Total Cash (Recent Filing): $1.86M
Total Debt (Recent Filing): $264.08K
Price to Earnings (P/E): ―
Beta: 3.25
Next Earnings: N/A
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Lipella Pharmaceuticals, Inc. News

Lipella Pharmaceuticals Begins Chapter 11 Bankruptcy Restructuring Process

Lipella Pharmaceuticals, Inc. ( ($LIPO) ) has shared an announcement. On March 30, 2026, Lipella Pharmaceuticals Inc. filed voluntary petitions for relief under Chapter 11 of the U.S. Bankruptcy Code

7M ago8K LIPO

Lipella Pharmaceuticals Announces Resignation of Board Member

Lipella Pharmaceuticals, Inc. ( ($LIPO) ) has shared an announcement. On February 3, 2026, Lipella Pharmaceuticals Inc. announced that board member Lori A. Birder resigned from the company’s Board of

9M ago8K LIPO

Lipella Pharmaceuticals Announces CMO Retirement

Lipella Pharmaceuticals, Inc. ( ($LIPO) ) just unveiled an announcement. On October 3, 2025, Dr. Michael Chancellor announced his retirement from Lipella Pharmaceuticals Inc., where he served as Chief Medical

1y ago8K LIPO

Lipella Pharmaceuticals Announces Positive Phase 2a Results

Lipella Pharmaceuticals, Inc. ( ($LIPO) ) has provided an update. On September 18, 2025, Lipella Pharmaceuticals announced positive final results from a completed Phase 2a study of LP-10, a proprietary

1y ago8K LIPO

Lipella Pharmaceuticals announces final results from Phase 2a study of LP-10

Lipella Pharmaceuticals (LIPO) announced final results from its completed Phase 2a multicenter, dose-ranging study evaluating LP-10, a proprietary liposomal tacrolimus oral rinse, in patients with symptomatic oral lichen planus. The

1y agoLIPO

Lipella Pharmaceuticals Announces Nasdaq Delisting

Lipella Pharmaceuticals, Inc. ( ($LIPO) ) has shared an announcement. On June 25, 2025, Lipella Pharmaceuticals announced its delisting from the Nasdaq Capital Market due to non-compliance with certain listing

1y ago8K LIPO

Lipella Pharmaceuticals Faces Nasdaq Delisting

Lipella Pharmaceuticals, Inc. ( ($LIPO) ) has issued an announcement. On June 20, 2025, Lipella Pharmaceuticals announced that its common stock was delisted from the Nasdaq Capital Market due to

1y ago8K LIPO

Lipella Pharmaceuticals announces U.S. patent issuance for diagnostic tech

Lipella Pharmaceuticals (LIPO) announced the issuance of U.S. Patent No. 12,326,492, titled “Systems and Methods of Detecting Interstitial Cystitis.” The patent was issued by the United States Patent and Trademark

1y agoLIPO

Lipella Pharmaceuticals Announces 2025 Stockholders Meeting Date

An announcement from Lipella Pharmaceuticals, Inc. ( ($LIPO) ) is now available. Lipella Pharmaceuticals Inc. has announced its 2025 annual meeting of stockholders will be held on July 21, 2025,

1y ago8K LIPO

Lipella Pharmaceuticals re-signs manufacturing collab with Cook MyoSite

Lipella Pharmaceuticals (LIPO) announced that it has re-signed its manufacturing collaboration agreement with Cook MyoSite to support Chemistry, Manufacturing and Control, CMC, documentation supporting our clinical products LP-10 and LP-310.

1y agoLIPO

Lipella Pharmaceuticals Faces Nasdaq Compliance Challenge

The latest update is out from Lipella Pharmaceuticals, Inc. ( ($LIPO) ). On May 12, 2025, Lipella Pharmaceuticals received a notice from Nasdaq indicating non-compliance with certain listing rules due

1y ago8K LIPO

Lipella Pharmaceuticals Presents Promising Phase 2a Trial Data

An announcement from Lipella Pharmaceuticals, Inc. ( ($LIPO) ) is now available. On May 15, 2025, Lipella Pharmaceuticals announced that topline data from its ongoing Phase 2a trial of LP-310

1y ago8K LIPO

Lipella Pharmaceuticals to present Phase 2a data for LP-310

Lipella Pharmaceuticals (LIPO) announced that topline data from the first two dose cohorts of its ongoing Phase 2a trial of LP-310 for the treatment of Oral Lichen Planus will be

1y agoLIPO

Lipella Reports Statistically Significant Results from Second Cohort in LP-310 Phase 2a Trial for Oral Lichen Planus

Pittsburgh, Pennsylvania, USA, April 23rd, 2025, Chainwire Findings reinforce localized efficacy profile; topline data from final dose group expected Q2 2025 Presentation of trial data to be delivered at 2025

1y agoLIPO

LIPO FAQ

What was Lipella Pharmaceuticals, Inc.’s price range in the past 12 months?

Lipella Pharmaceuticals, Inc. lowest stock price was $0.02 and its highest was $0.64 in the past 12 months.

What is Lipella Pharmaceuticals, Inc.’s market cap?

Lipella Pharmaceuticals, Inc.’s market cap is $2,773.

When is Lipella Pharmaceuticals, Inc.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Lipella Pharmaceuticals, Inc.’s earnings last quarter?

Lipella Pharmaceuticals, Inc. released its earnings results on Mar 31, 2023. The company reported -$1.487 earnings per share for the quarter.

Is Lipella Pharmaceuticals, Inc. overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Lipella Pharmaceuticals, Inc. pay dividends?

Lipella Pharmaceuticals, Inc. does not currently pay dividends.

What is Lipella Pharmaceuticals, Inc.’s EPS estimate?

Lipella Pharmaceuticals, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Lipella Pharmaceuticals, Inc. have?

Lipella Pharmaceuticals, Inc. has 4,620,837 shares outstanding.

What happened to Lipella Pharmaceuticals, Inc.’s price movement after its last earnings report?

Lipella Pharmaceuticals, Inc. reported an EPS of -$1.487 in its last earnings report. Following the earnings report the stock price went down -1.588%.

Which hedge fund is a major shareholder of Lipella Pharmaceuticals, Inc.?

Currently, no hedge funds are holding shares in LIPO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description